Dissecting the rationale for thromboprophylaxis in challenging surgical cases

J Thromb Haemost. 2024 Mar;22(3):613-619. doi: 10.1016/j.jtha.2023.12.033. Epub 2024 Jan 4.

Abstract

Pulmonary embolism (PE) is a leading preventable cause of death in surgical patients, and rates of fatal PE are increasing. Individual assessment, to balance the risks of thrombosis and bleeding, is the key to providing appropriate prophylaxis. The risk assessment process includes use of evidence-based guidelines, literature published since the latest guidelines, large registries, and risk scoring systems together with clinical experience and judgment. Risk assessment is a dynamic process and needs to be updated both during the hospital stay and just prior to discharge since clinical events may change the level of risk. The final assessment may identify patients who require ongoing anticoagulant prophylaxis after discharge. The Caprini risk score is widely used in surgical patients and is a composite of the number of risk factors and their relative weights. The Caprini risk score set point for risk levels requiring anticoagulant prophylaxis varies depending on the type of surgical procedure, surgical population, and number of risk factors. Mandatory implementation of evidence-based care pathways is helpful in lowering PE-related mortality. This review presents several challenging cases, emphasizing the importance of employing all available assessment tools, including dynamic assessment of risk during hospitalization. Finally, the limitations of evidence-based guidelines in complex scenarios and the need to employ all available tools to properly protect very high-risk patients are emphasized.

Keywords: Caprini risk score; prophylaxis; risk assessment; thromboembolism.

Publication types

  • Review

MeSH terms

  • Anticoagulants / adverse effects
  • Humans
  • Pulmonary Embolism* / drug therapy
  • Pulmonary Embolism* / etiology
  • Pulmonary Embolism* / prevention & control
  • Risk Assessment
  • Risk Factors
  • Thrombosis* / drug therapy
  • Venous Thromboembolism* / epidemiology

Substances

  • Anticoagulants